InflaRx (NASDAQ:IFRX – Get Free Report) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare InflaRx to related companies based on the strength of its dividends, profitability, risk, valuation, institutional ownership, earnings and analyst recommendations.
Analyst Recommendations
This is a summary of current recommendations for InflaRx and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| InflaRx | 1 | 2 | 5 | 1 | 2.67 |
| InflaRx Competitors | 9869 | 15283 | 45611 | 1598 | 2.54 |
InflaRx presently has a consensus price target of $7.43, indicating a potential upside of 526.88%. As a group, “Biotechnology” companies have a potential upside of 122.45%. Given InflaRx’s stronger consensus rating and higher probable upside, equities analysts plainly believe InflaRx is more favorable than its rivals.
Risk and Volatility
InflaRx has a beta of 2.38, suggesting that its stock price is 138% more volatile than the S&P 500. Comparatively, InflaRx’s rivals have a beta of -1.85, suggesting that their average stock price is 285% less volatile than the S&P 500.
Earnings and Valuation
This table compares InflaRx and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| InflaRx | $30,000.00 | -$51.63 million | -3.04 |
| InflaRx Competitors | $756.66 million | $13.58 million | -19.08 |
InflaRx’s rivals have higher revenue and earnings than InflaRx. InflaRx is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares InflaRx and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| InflaRx | N/A | -32.04% | -27.33% |
| InflaRx Competitors | -12,323.33% | -195.38% | -30.39% |
Insider and Institutional Ownership
42.4% of InflaRx shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 16.3% of InflaRx shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
InflaRx beats its rivals on 9 of the 13 factors compared.
About InflaRx
InflaRx N.V. is a biotechnology company that develops therapies for inflammatory and autoimmune diseases. Its research focuses on the complement system, a part of the immune system that can contribute to inflammation and tissue damage. The company’s lead antibody, vilobelimab, targets the complement protein C5a. In 2023, the U.S. Food and Drug Administration granted emergency use authorization for vilobelimab, marketed as Gohibic, for certain hospitalized adults with COVID-19. InflaRx is also investigating the drug in other inflammatory conditions.
Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.
